Vyome Holdings (HIND) Receivables - Other (2015 - 2026)

Vyome Holdings (HIND) posted quarterly Receivables - Other of $579335.0 for Q1 2026, up 489.44% quarter-over-quarter from $98286.0 in Q4 2025.

Vyome Holdings (HIND) Receivables - Other (2015 - 2026) Analysis & Trends

Vyome Holdings' Receivables - Other history runs 9 years deep, the most recent figure standing at $579335.0 for Q1 2026.

In Q1 2026, Receivables - Other changed N/A year-over-year to $579335.0; the TTM figure through Mar 2026 stood at $579335.0 (changed N/A YoY), while the FY2025 annual figure was $601537.0, down 6.99% from the prior year.
Receivables - Other for Q1 2026 stood at $579335.0, up from $98286.0 in the prior quarter.
The five-year high for Receivables - Other was $646758.0 in Q4 2024, with the low at $98286.0 in Q4 2025.
The 3-year median for Receivables - Other is $593124.5 (2025), against an average of $482823.2.
Peak annual rise in Receivables - Other reached 84.8% in 2025, while the deepest fall reached 84.8% in 2025.
Vyome Holdings' Receivables - Other stood at $646758.0 in 2024, then slumped by 84.8% to $98286.0 in 2025, then jumped by 489.44% to $579335.0 in 2026.
Business Quant data shows HIND's Receivables - Other at $579335.0 in Q1 2026, $98286.0 in Q4 2025, and $606914.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.19 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.58 Bn	77.59 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.34 Bn	1.37 Bn
4	Moderna	56.52 Bn	51.38 Bn	52.00 Mn
5	BeOne Medicines	42.04 Bn	36.94 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.67 Bn	27.36 Bn	992.69 Mn
7	Insmed	27.27 Bn	26.11 Bn	358.27 Mn
8	BioNTech SE	27.14 Bn	8.75 Bn	668.28 Mn
9	Royalty Pharma	27.12 Bn	26.28 Bn	-
10	Vyome Holdings	16.28 Mn	9.66 Mn	11,658.00

Download Data